According to estimates from 5 analysts, the average price target for Acrivon Therapeutics, Inc. shares has decreased from $11.50 to $10; forecasts range from $7 to $14 per share
Based on the closing price on November 20, 2026, the new price target implies upside potential of around 770%
The consensus rating from 6 analysts remains “Buy” (buy — 6, hold — 0, sell — 0)